Kimball Electronics, Inc. — Form 10-Q Summary
Business context and reporting period
Kimball Electronics is a global contract electronics manufacturer serving automotive, medical, industrial, and public safety markets. This unaudited filing covers the three months ended September 30, 2015, the first quarter of fiscal 2016. The company became independent in October 2014; the comparable 2014 quarter included allocations from its former parent and may not reflect costs as a standalone company.
Financial performance and liquidity
| Metric | Q1 FY2016 | Q1 FY2015 |
|---|---|---|
| Net sales | $200.4 million | $203.8 million |
| Gross profit / margin | $15.3 million / 7.6% | $17.9 million / 8.8% |
| Operating income / margin | $6.9 million / 3.5% | $7.8 million / 3.8% |
| Net income | $4.5 million | $5.4 million |
| Diluted EPS | $0.15 | $0.18 |
| Net cash used for operating activities | $0.5 million | $4.5 million |
| Net cash used for investing activities | $11.1 million | $7.7 million |
Cash was $52.7 million at September 30, down from $65.2 million at June 30. Working capital was $192.4 million and the current ratio was 2.3. Short-term liquidity, including cash and unused credit facilities, was $112.4 million. There were no borrowings under the primary or disclosed foreign credit facilities; the company reported covenant compliance. The primary revolving facility provides up to $50 million, with an option to increase to $75 million, and matures in October 2019.
Material changes versus the prior comparable period
- Sales declined 2%; gross profit fell 15%, operating income fell 11%, and net income fell 17%. Gross margin contracted by 1.2 percentage points.
- Management attributed the margin decline to lower sales leverage, new-product introduction costs, and foreign-exchange fluctuations. Selling and administrative expense declined 17%, aided by lower spin-off costs and the absence of certain former-parent allocations.
- By market, automotive sales rose 1%, medical fell 5%, industrial fell 8%, and public safety rose 16%. Open orders were down 3% year over year.
- Operating cash use improved from the prior-year quarter, but working capital still used $14.0 million of cash, primarily from higher inventory, lower accounts payable, and incentive-compensation payments.
Outlook, commentary, and risks
Management expected moderate EMS-market growth with mixed demand, noting relative strength in U.S. and China automotive markets but slowing China growth, weaker industrial climate-control demand, stable medical demand, and improving public-safety demand. No quantified revenue or earnings guidance was provided. Management expected available cash, operating cash generation, and borrowing capacity to meet needs for at least 12 months.
The company was expanding European capacity with a greenfield facility in Romania, anticipated to begin operations mid-fiscal year; capital-expenditure commitments were approximately $14 million. On October 21, 2015, the board authorized an 18-month stock-repurchase program of up to $20 million, expected to be funded from existing liquidity; repurchases may be suspended or discontinued.
Key risks include customer/program concentration and cancellations, replacement of expiring programs, demand fluctuations, competitive pricing, component availability, customer or supplier financial stress, foreign-exchange movements, and the ability to manage capacity and working capital. The company reported no material change to previously disclosed risk factors and no material pending legal proceedings. Outstanding transferred China banker’s acceptance drafts with recourse totaled $2.2 million; no recourse claims had been made. Standby letters of credit exposed the company to a maximum $0.3 million, with no liability recorded.
Important facts for investors to verify
- Whether sales and margins stabilize as JCI program volumes decline and new business replaces them.
- Whether the Romania expansion and new program introductions deliver expected growth without sustained margin or cash-flow pressure.
- Inventory growth, customer forecasts, and working-capital conversion, including the quarter’s operating cash use.
- Actual timing and scale of the authorized buyback and its effect on cash and investment capacity.
- Foreign-exchange hedge exposures and the estimated $4.3 million pretax derivative loss expected to be reclassified into earnings within 12 months, alongside the related hedged transactions.